Innovative MedTech (Innovative MedTech) Cash-to-Debt : 0.04 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Innovative MedTech's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.04.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Innovative MedTech couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Innovative MedTech's Cash-to-Debt or its related term are showing as below:

IMTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.07 Max: 0.19
Current: 0.04

During the past 13 years, Innovative MedTech's highest Cash to Debt Ratio was 0.19. The lowest was 0.00. And the median was 0.07.

IMTH's Cash-to-Debt is ranked worse than
96.29% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 1.935 vs IMTH: 0.04

Innovative MedTech Cash-to-Debt Historical Data

The historical data trend for Innovative MedTech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Innovative MedTech Cash-to-Debt Chart

Innovative MedTech Annual Data

Trend

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

0.19

0.13

0.07

Innovative MedTech Quarterly Data
	Oct13	Jan14	Apr14	Jul14	Oct14	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.04	0.09	0.07	0.11	0.04

Competitive Comparison of Innovative MedTech's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Innovative MedTech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovative MedTech's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innovative MedTech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Innovative MedTech's Cash-to-Debt falls into.

Innovative MedTech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Innovative MedTech's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.158	/	(1.497	+	0.682)
	=	0.07

Innovative MedTech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.093	/	(1.621	+	0.668)
	=	0.04

Innovative MedTech (OTCPK:IMTH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Innovative MedTech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative MedTech (Innovative MedTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2310 York Street, Suite 200, Blue Island, IL, USA, 60406

Website

https://www.innovativemedtech.com

Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: the RX Vitality digital wallet and health care app.

Executives

Merle Griff	officer: Chief Executive Officer	2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner	10 percent owner	70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt	director, 10 percent owner, other: Chairman of the Board	2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman	10 percent owner	280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts	10 percent owner	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman	director, 10 percent owner, officer: President & CEO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc.	10 percent owner	881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine	director, officer: CFO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari	director, officer: COO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz	director	280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo	director, officer: President	3163 KENNEDY BLVD, JERSEY CITY NJ 07306